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Background: A variety of pharmacological and surgical treatments have been developed for heavy menstrual
bleeding (HMB), which can have negative physical, social, psychological, and economic consequences. We
conducted a systematic literature review and mixed-treatment-comparison (MTC) meta-analysis of available data
from randomized controlled trials (RCTs) to derive estimates of efficacy for 8 classes of treatments for HMB, to
inform health-economic analysis and future studies.
Methods: A systematic review identified RCTs that reported data on menstrual blood loss (MBL) at baseline and
one or more follow-up times. Eight treatment classes were considered: COCs, danazol, endometrial ablation, LNG-
IUS, placebo, progestogens given for less than 2 weeks out of 4 during the menstrual cycle, progestogens given for
close to 3 weeks out of 4, and TXA. The primary measure of efficacy was the proportion of women who achieved
MBL < 80 mL per cycle (month), as measured by the alkaline hematin method. A score less than 100 on an
established pictorial blood-loss assessment chart (PBAC) was considered an acceptable substitute for MBL < 80 mL.
Estimates of efficacy by treatment class and time were obtained from a Bayesian MTC model. The model also
included effects for treatment class, study, and the combination of treatment class and study and an adjustment for
baseline mean MBL. Several methodological challenges complicated the analysis. Some trials reported various
summary statistics for MBL or PBAC, requiring estimation (with less precision) of % MBL < 80 mL or % PBAC < 100.
Also, reported follow-up times varied substantially.
Results: The evidence network involved 34 RCTs, with follow-up times from 1 to 36 months. Efficacy at 3 months
of follow-up (estimated as the posterior median) ranged from 87.5% for the levonorgestrel-releasing intrauterine
system (LNG-IUS) to 14.2% for progestogens administered for less than 2 weeks out of 4 in the menstrual cycle. The
95% credible intervals for most estimates were quite wide, mainly because of the limited evidence for many
combinations of treatment class and follow-up time and the uncertainty from estimating % MBL < 80 mL or %
PBAC < 100 from summary statistics.
Conclusions: LNG-IUS and endometrial ablation are very efficacious in treating HMB. The study yielded useful insights
on using MTC in sparse evidence networks. Diversity of outcome measures and follow-up times in the HMB literature
presented considerable challenges. The Bayesian credible intervals reflected the various sources of uncertainty.* Correspondence: radek.wasiak@unitedbiosource.com
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Figure 1 Summary of the literature search process.
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Heavy menstrual bleeding (HMB) is a common but empiric-
ally challenging health condition. Although HMB is defined
as menstrual flow exceeding 80 milliliters (mL) of blood loss
per menstrual cycle that cannot be explained by organic
pathology or medical illness, [1] the diagnosis is subjective,
at least initially, and women vary in their perceptions of
what is acceptable blood loss and when to seek help.
In surveys, between 13% and 52% of women report hav-
ing HMB, depending on the country, age group, and defin-
ition of HMB [2-5]. However, fewer than 1 in 5 women
who met criteria for HMB in England had sought treat-
ment from their general practitioner [6]. Another study
found that only one third of women referred to a
gynecology clinic in Scotland for HMB actually had a mean
menstrual blood loss (MBL) greater than 80 mL when this
was formally measured, [7] suggesting a more conservative
prevalence of HMB between 11% and 13% [2].
HMB can have negative physical, social, psychological,
and economic consequences. MBL greater than 80 mL is
likely to lead to anemia, [1] which affected around one
quarter of women hospitalized for HMB in one US study
[8]. HMB also impairs a woman’s quality of life [2] and is
associated with a reduced likelihood of being employed [5].
A variety of pharmacological and surgical treatments aim
to reduce MBL or eliminate menstruation altogether. Classes
of treatments include combined oral contraceptives (COCs),
tranexamic acid (TXA), oral or injectable progestogens, da-
nazol, the levonorgestrel-releasing intrauterine system (LNG-
IUS), and endometrial ablation or resection. An informed
choice requires information on the clinical efficacy of rele-
vant treatment options. In previous systematic reviews the
evidence base on this topic has been weak, with few direct
comparisons among treatment options, [9-12] leading to un-
certainty about the overall comparative effectiveness of the
most commonly used treatments. We therefore conducted a
systematic literature review and mixed-treatment-compari-
son (MTC) meta-analysis to inform the development of a
microsimulation model that assessed the cost-effectiveness of
pharmacological interventions and endometrial ablation for
HMB [13]. A type of network meta-analysis, MTCs combine
information from direct and indirect comparisons of inter-
ventions, to allow estimation of the relative efficacy of
interventions that have not been directly compared in head-
to-head studies [14]. Our focus, however, was on estimating
absolute efficacy (for use in the microsimulation model), ra-
ther than on assessing relative efficacy. During the review
and analysis we identified a number of methodological chal-
lenges that should inform future research.
Methods
Treatments compared
We considered eight treatment classes: COCs, danazol,
endometrial ablation, LNG-IUS, placebo, progestogensgiven for less than 2 weeks out of 4 during the menstrual
cycle, progestogens given for close to 3 weeks out of 4,
and TXA. We made no distinction between first- and
second-generation endometrial ablation techniques.
Literature search
Figure 1 summarizes the literature search process. Most
of the articles that provided data for the present analysis
were identified as part of a systematic review of the lit-
erature on HMB, covering the period 1966–2009. That
review included a replication and update of a literature
review previously employed for the National Institute for
Health and Clinical Excellence (NICE) HMB guideline
[2]. The search used the Cochrane Library, MEDLINE,
EMBASE, CINAHL, PsychINFO, and the National Health
Service (NHS) Economic Evaluation Database and in-
cluded manual searches of the bibliographies of all review
articles, as well as ad hoc internet searches for key
treatment-related terms.
The titles and abstracts of the resulting items were
reviewed against predefined inclusion and exclusion cri-
teria. (See Additional file 1 for the inclusion and exclu-
sion criteria for the full search and for studies of
efficacy.) Items that had not been excluded were
reviewed in full text, and data were extracted from items
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cations in the period 2009–2011 were identified through
a manual search. Extracted data were reviewed for ac-
curacy and completeness by an independent researcher.
Articles were assessed for quality using the Centre for
Evidence Based Medicine (CEBM), (University of Oxford)
quality score and the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) score [15].
Efficacy measures
The primary measure of efficacy was the proportion of
women who achieved MBL < 80 mL per cycle (month), as
measured by the alkaline hematin method [16,17]. This
measure allows objective estimation of blood loss, provided
the patient accurately collects all sanitary material and sub-
mits it for analysis. As a less burdensome substitute, several
researchers have developed pictorial charts, on which the
patient records the blood loss by its appearance on various
types of sanitary material; an investigator then uses a scoring
system to calculate a numerical score for the cycle. The
most widely used is the pictorial blood-loss assessment chart
(PBAC) developed by Higham et al. [18], for which a score
less than 100 is considered equivalent to MBL < 80 mL.
The choice of MBL as the efficacy measure was deter-
mined mainly by the outcomes reported in the random-
ized controlled trials (RCTs). A patient-reported outcome
would enhance generalizability and relevance of the re-
sults, but inconsistent use of different scales with unclear
psychometric properties for the HMB population made
such a measure infeasible [19].
We extracted data if authors used the alkaline hematin
method to measure blood loss, or if subjects used the
Higham PBAC chart to assess their blood loss. Studies
in which MBL was objectively measured could report
the mean or median MBL with an accompanying meas-
ure of spread, or the proportion of women who achieved
MBL < 80 mL per menstrual cycle at a particular follow-
up time. The latter data were directly used as inputs for
the analysis. We estimated the proportion of women
with MBL < 80 mL from mean MBL data (with spread)
and from median MBL data (with spread). These esti-
mated proportions, along with estimates of their stand-
ard errors, were then used as inputs for the analysis.
Data on the proportion of women with a PBAC score <
100 were also used directly as inputs. When studies
reported a mean PBAC (with spread) or a median PBAC
(with spread), we estimated the proportion of women
with PBAC < 100 and used these estimates, along with
estimates of their standard errors, as inputs. Additional
file 2 discusses these calculations in more detail.
Statistical model
A Bayesian statistical model related data on % MBL < 80
mL (or % PBAC < 100) to study, treatment class, andfollow-up time. The outcomes of main interest were the
estimated percentage of women who achieved MBL < 80
mL for various combinations of treatment class and
follow-up time. The model included effects for treat-
ment class, the combination of treatment class and time,
study, and the combination of treatment class and study.
The presence of a study effect preserved the effect of
randomization within study.
The efficacy of treatments in achieving MBL < 80 mL
may depend on the baseline severity of HMB, measured
as baseline MBL. We adjusted for study-level differences
in mean baseline MBL by including this as a covariate in
the Bayesian model. Thus, the predicted proportion of
women with MBL < 80 mL corresponds to a mean base-
line MBL equal to the overall average of the mean base-
line MBL data reported by all source studies, 170 mL.
In the specification of the model, yijt denotes the num-
ber of women with MBL < 80 mL (or PBAC < 100)
among the nijt in study i who were assigned to a treat-
ment in treatment class j and were present at follow-up
time t. The probability model for yijt is
yijt∼Binomial nijt ; pijt
 
and the model for pijt is logit-linear:
logit pijt
 
¼ α0 þ ηi þ θij þ γ jt
where logit(p) = loge(p/(1–p)), α0 is the intercept term,
ηi is the random effect for study i, θij is the random ef-
fect for the interaction of treatment class j and study i,
and γjt is the incremental effect for follow-up time t spe-
cific to treatment class j. The model treats studies with
multiple follow-up times as having the same values of ηi
and θij for each observation, but potentially different γjt .
The θij have a random-effects distribution, conditional
on treatment-class-specific parameters:
θij∼Normal δj þ α1xij; τ2j
 
where δj is the treatment-class effect, xij is the baseline
mean MBL for the arm in treatment class j in study i
(standardized by subtracting the mean over all combina-
tions of i and j with non-missing values and dividing by
the corresponding standard deviation), α1 provides the
adjustment for xij, and τ2j is the conditional variance of
the θij given δj and α1 .
Further, the study effects have a random-effects distri-





The model uses a proper, but weakly informative, prior
distribution for all parameters. The prior components
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are:
α0 ~ Normal (0, 10
4)
γjt ~ Normal (0, 100)
δj ~ Normal (0, 10
4), independent
α1 ~ Uniform (−5, 5)
τj ~ Uniform (0, 100), independent
1=σ2η ~ Gamma (0.1, 0.1)
These prior components are conventional choices. A
uniform prior distribution on a standard deviation such
as τj is recommended by Gelman and Hill [20].
Missing values of baseline mean MBL were considered
to be missing at random [21]. A prior distribution com-
ponent was used for the missing standardized mean
MBL values:
xij∼Normal 0; 1ð Þ
Importantly, although the prior distributions on the
missing values are centered at 0, other information in
the model moves posterior inferences away from 0.
Implementation
Estimates of efficacy and all model parameters were
obtained through Markov chain Monte Carlo (MCMC)
simulation from the posterior distributions. The MCMC
simulation for the MTC was implemented using
OpenBUGS software (version 3.1.2) [22]. (Three parallel
MCMC simulations were run for a burn-in period of












Figure 2 Evidence network of RCTs for MBL in HMB.saved for posterior summaries.) Convergence was
assessed through trace plots of several model parameters
and a plot of the Gelman-Rubin diagnostic as modified
by Brooks and Gelman [23].Results
Literature search
A total of 355 articles met the inclusion and exclusion
criteria for efficacy. The review of the full text excluded
310 articles for the reasons listed in Additional file 1
The majority of the excluded articles did not report
measures of efficacy suitable for the analysis (i.e., MBL
or the PBAC score of Higham et al. [18]).
After all inclusion and exclusion criteria were applied,
a total of 45 efficacy studies remained: 32 RCTs and 13
observational studies. The present analysis used only the
RCTs. Assessment of the literature published after 2009
found 2 additional RCTs and a later article on one of the
initial 32. Thus, efficacy data were available from a total
of 34 RCTs; a table summarizing characteristics of the
studies is available upon request.Evidence network
Among the 34 RCTs, the most studied treatment classes
were ablation (16 RCTs) and LNG-IUS (11 RCTs). Figure 2
shows the treatment classes and direct comparisons that
comprised the evidence network. The total number of dir-
ect comparisons between treatment classes, 21, differs
from the number of RCTs, because 9 studies compared
two types of ablation, 1 study had three arms (progesto-
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studies evaluated treatments not of interest for this study.
The network is thinly connected: only two pairs of
treatment classes have more than two direct compari-
sons, and seven have only one. Only at 3 months are all
8 treatment classes connected (Table 1). At other follow-
up times, the number of treatment classes involved in
any direct comparison ranges from 7 (at 1 month) to 2
(at 9, 24, and 36 months); at 1 month the network sepa-
rates into three disjoint components. The trial of LNG-
IUS and TXA reported efficacy for the two arms at dis-
joint times (3, 6, and 12 months for LNG-IUS, and 2
months for TXA) and hence did not provide any direct
comparison.
The total number of patients for a given direct compari-
son (based on the maximum number reported, usually at
baseline) was often modest: 4 of the comparisons had
fewer than 50 patients, and the largest number was 422.
Efficacy measures
The data on efficacy had a variety of forms: 11 studies
reported the proportion of women achieving MBL < 80
mL; 5 studies reported mean and standard deviation of
MBL, and 3 reported median and minimum and max-
imum of MBL; 11 studies reported the proportion of
women with PBAC < 100, 8 studies reported mean and
standard deviation of PBAC, 2 reported median and
quartiles of PBAC, and 1 reported median and minimum
and maximum of PBAC. Several studies reported moreTable 1 Comparisons in the evidence network: Number of
RCTs that made the comparison, total number of patients
in those RCTs, and number of direct comparisons by
follow-up time
Total N Number of Comparisons
Follow-up Time (Months)
Comparison RCTs 1 2 3 6 9 12 24 36
Ablation & LNG-IUS 7 422 1 2 7 2 1
COC & Danazol 1 24 1
COC & Placebo 2 355 2 2 2 2
COC & LNG-IUS 2 91 1 1 1 2
Danazol &
Prog < 2 wks
3 72 1 1 3
Placebo & TXA 1 166 1
LNG-IUS &
Prog < 2 wks
1 162 1 1
LNG-IUS &
Prog ~ 3 wks
1 38 1 1
LNG-IUS & TXA 1 31
Prog < 2 wks &
TXA
1 46 1 1
Prog ~ 3 wks &
TXA
1 94 1than one form, even different forms at different follow-
up times for the same arm. The data extraction gave
preference to the proportion of women with MBL < 80
mL over summary statistics for MBL when both were
available, and similarly for PBAC. For four studies
[24-27], we obtained data on the proportion of women
with MBL < 80 mL or PBAC < 100 from a clinical study
report or a subsequent analysis.
Only 15 studies reported a mean of MBL at baseline,
ranging from 90.3 mL to 300 mL. The average (over
study arms with non-missing data) was 169.64 mL.Posterior summaries
In line with convention we report posterior medians
with 95% credible intervals (CrI) (whose endpoints are
the 2.5 and 97.5 percentage points of the posterior dis-
tribution). Table 2 presents these estimates of efficacy at
3 months (the interval at which patients in the economic
model were evaluated). Because the statistical model ad-
justs for the baseline mean of MBL, those estimates are
stated at a baseline MBL of 169.64 mL.
Based on available data, estimates after 3 months of
treatment indicate the following descending order of ef-
ficacy (posterior median): LNG-IUS and endometrial ab-
lation with comparably high response rates (87.5% and
81.6% of women achieving MBL < 80 mL, respectively),
followed by danazol (65.8%), progestogens given for
close to 3 weeks out of 4 during the menstrual cycle
(63.6%), COCs (63.4%), and TXA (48.2%). Progestogens
administered for less than 2 weeks out of 4 (14.2%) were
not better than placebo (17.7%).
The widths of the 95% credible intervals range from
16 percentage points for LNG-IUS to 94 percentage
points for ablation. Among the other six treatment clas-
ses, four widths range from 28 to 38 percentage points,
one is 59, and the other is 75. Thus, most estimates had
substantial uncertainty. Only LNG-IUS and COCs had
credible intervals that did not overlap the interval for
placebo.Table 2 Efficacy estimates for the 8 treatment classes at 3
months








Prog < 2wks 14.2 (3.7−41.7)
Posterior median with 95% CrI.
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The MTC framework was convenient for synthesizing
available evidence and estimating % MBL < 80 mL at
various follow-up times, but our focus was not on com-
paring treatment classes, nor on comparing treatments
within classes (the data generally were not sufficient).
The validity and reliability of the evidence for com-
pounds within the same class (e.g., COCs) varies among
studies, and pooled estimates for treatment classes may
not account for some variation in efficacy within the
class. The main aim was to estimate efficacy at a follow-
up time of 3 months, with corresponding credible inter-
vals, as inputs in a microsimulation economic model
evaluating the relative cost and health impact of the
eight treatment classes. The analysis produced posterior
median estimates of % MBL < 80 mL that plausibly re-
flect the current evidence: a high level of efficacy for
LNG-IUS and endometrial ablation [28] and somewhat
lower efficacy for oral treatments. LNG-IUS and abla-
tion, however, are designed for long-term (1 year or lon-
ger) reduction of menstrual bleeding. For women who
prefer oral treatments and reversible contraception,
COCs are an appropriate option.
Our evidence synthesis used a Bayesian framework, ra-
ther than a frequentist analysis, because Bayesian
methods for indirect comparisons and MTCs are much
more fully developed, offer greater flexibility in handling
the special features of our data (e.g., availability of both
direct and indirect evidence for some comparisons, un-
certainty of % MBL < 80 mL and % PBAC < 100 esti-
mated from summary statistics, accounting for missing
data), and avoid problems associated with inverse-
variance weighting based on estimated variances, such as
bias and confidence-interval coverage that departs sub-
stantially from the nominal value [29]. However, the use
of a treatment-class effect, rather than treatment-specific
effects within a class, may not fully account for some
variation in efficacy between interventions within the
same class.
A number of systematic reviews have synthesized the evi-
dence for subsets of the treatment classes, and a network
meta-analysis compared six second-generation endometrial
ablation techniques (primarily with the class of first-
generation hysteroscopic devices as the reference treatment)
[30]. However, this is the first study that has combined data
on eight treatment options for heavy menstrual bleeding.
The systematic reviews comparing LNG-IUS and
endometrial ablation have produced inconsistent conclu-
sions. Marjoribanks et al. [31] concluded that resection
or ablation was more effective than LNG-IUS at control-
ling bleeding at 1 year, but the evidence for longer-term
effects was inconclusive. Lethaby et al. [12], addressing
the same comparison from the opposite perspective, also
found that LNG-IUS produced a smaller mean reductionin MBL (the primary endpoint) than ablation and pro-
gestogen side effects, but with no evidence of a differ-
ence in satisfaction or perceived quality of life between
LNG-IUS and ablation. In contrast, Kaunitz et al. [32]
subsequently used trial-level means and standard devia-
tions of PBAC scores (their primary endpoint) from six
RCTs to compare LNG-IUS and ablation. They con-
cluded that at 6, 12, and 24 months, LNG-IUS was at
least as effective as ablation in reducing MBL.
Middleton et al. [33] identified 30 RCTs that compared
pairs of treatments from the classes first-generation ab-
lation, second-generation ablation, LNG-IUS, and hys-
terectomy, and assembled individual patient data (IPD)
from 17 of them. The primary outcome measure was
satisfaction, but they also analyzed available data on
MBL. Having IPD allowed them “to use previously unre-
ported data, improve the assessment of study quality,
standardize outcome measures, undertake intention-
to-treat analysis, and use optimal analytical methods.” In
their analysis LNG-IUS and endometrial ablation were
comparable, but the authors remarked on uncertainty
from small sample sizes in studies of LNG-IUS.
The findings of these systematic reviews of direct com-
parisons add support to the indication from our analysis
that ablation is an effective treatment for HMB.
Lethaby et al. also evaluated a number of pharmaco-
logical therapies for HMB in a series of systematic reviews.
They concluded that oral progestogens administered only
during the luteal phase were less effective at reducing
MBL than tranexamic acid, danazol, and LNG-IUS. Pro-
gestogens taken between day 5 and day 26 of the cycle,
however, significantly reduced MBL from baseline, but
were less effective than LNG-IUS [10,12]. Danazol seemed
to be more effective than placebo, progestogens, or COC,
but confidence intervals were wide (based on pooled data
from nine RCTs) [34]. Tranexamic acid was more effective
than placebo and luteal-phase progestogens at reducing
MBL [11]. An additional review of the effect of COCs on
MBL by Farquhar and Brown [9] located only one cross-
over study of 45 women, which found no significant differ-
ence in MBL between COC and danazol or non-steroidal
anti-inflammatory drugs. Marjoribanks et al. [31] con-
cluded that the results of these reviews “suggest that the
LNG-IUS system provides a better alternative to surgery
than oral medication. Levels of satisfaction and quality of
life reported by women with an LNG-IUS system are
similar to those in women who have undergone trans-
cervical endometrial ablation or balloon ablation. Surgical
methods are significantly more effective in reducing bleed-
ing at one year, but studies with longer follow up did not
show an ongoing advantage for surgery.”
These systematic reviews therefore agree with the esti-
mates from our MTC that LNG-IUS and ablation are
the most effective of the treatments studied at reducing
Hoaglin et al. European Journal of Medical Research 2013, 18:17 Page 7 of 9
http://www.eurjmedres.com/content/18/1/17MBL, that progestogens given for less than 2 weeks out
of 4 during the menstrual cycle are least effective, and
that danazol, progestogens given for close to 3 weeks
out of 4, and tranexamic acid also showed efficacy. Our
MTC was able to produce stronger evidence to support
the use of COCs in HMB, largely by identifying studies
that were not published at the time of the review by
Farquhar and Brown [9]. The previous systematic reviews
found no direct-comparison studies for oral progestogens
versus placebo, danazol versus TXA, danazol versus LNG-
IUS, or LNG-IUS versus placebo, but our MTC suggested
comparative efficacy for these treatments.
As mentioned in the introduction, we encountered sev-
eral methodological challenges. First, the limited amount
of data available contributed to the substantial uncertainty
in most of our estimates of efficacy. Most of the studies
had fairly modest sample sizes (median number of pa-
tients per arm 33, range 9 to 164). Also, as indicated earl-
ier, studies varied greatly in the measures used and in
study designs; 21 direct comparisons were spread among
8 treatment classes, and only one pair of treatment classes
had more than 3 direct comparisons (Figure 1).
Further, the small number of follow-up times that
were common across treatment classes (Table 1) in-
creased uncertainty. Some variation in follow-up time is
a consequence of the nature of the treatment classes.
For example, for endometrial ablation, follow-up times
of 6, 12, and 24 months are common. Among the seven
studies that compared ablation and LNG-IUS, only one
reported efficacy at 3 months. Thus, the wide credible
interval at 3 months (94 percentage points) is not sur-
prising. For other treatment classes (e.g., danazol and
TXA), follow-up times of 1, 2, 3, and 6 months are more
appropriate. The apparent lack of consensus on follow-
up times among researchers studying a particular treat-
ment class presents a challenge for evidence synthesis.
Estimation of % MBL < 80 mL (or % PBAC < 100)
from summary statistics for MBL (or PBAC) introduced
additional uncertainty, and each of the three distinct sets
of summary statistics (mean and standard deviation, me-
dian and minimum and maximum, and median and
quartiles) required a separate procedure for estimating %
MBL < 80 mL or % PBAC < 100 (and a further, more-
complicated procedure for estimating the standard error
of the estimate). We wanted, however, to use as much of
the available evidence as possible. In some articles we
were unable to extract the same measure of efficacy at
all follow-up times, or even for both treatments. Investi-
gators showed little consensus on the measures of effi-
cacy to report, with no convergence of approach over
time. Future researchers can facilitate meta-analyses and
MTCs by reporting outcomes in a more consistent way
and in sufficient detail (e.g., in a supplemental file, avail-
able online) for secondary analysis.The greater use of measures based on PBAC scores may
reflect a shift away from the burden that use of MBL
places on trial participants (who must collect their sanitary
material for laboratory analysis). We used only data based
on the PBAC score developed by Higham et al. [18] be-
cause it was much more common in the articles that we
encountered than scores based on other pictorial charts.
The validity of both PBAC and the alkaline hematin
method requires consistent use of the specific validated
sanitary materials. Deviations from this requirement may
affect estimates of efficacy; but they are difficult to meas-
ure and are not reported in the studies’ results, adding to
unexplained variation and uncertainty of the estimates.
In some MTC meta-analyses it may be advantageous to
include RCTs that evaluated only one, or even none, of
the treatments of interest [35]. When comparisons of effi-
cacy are the focus, the network of evidence would then or-
dinarily include all the treatments evaluated in those
RCTs. Five of the RCTs in our data evaluated treatments
that were not considered in the microsimulation model,
and we did not include data from the other arms of those
RCTs. In four of the five, the other treatment was
mefenamic acid (which is no longer considered a strong
treatment option), and in the fifth it was hysterectomy.
Several areas would benefit from attention in future
work: the effect of including additional treatment classes
in the evidence network, including RCTs that reported
outcomes based on other pictorial charts, incorporating
results from observational studies, and synthesizing evi-
dence on patient-focused outcomes such as satisfaction
and health-related quality of life.
Conclusions
Synthesis of the evidence in an MTC framework yielded
plausible estimates of % MBL < 80 mL at 3 months for
the eight treatment classes. LNG-IUS and endometrial ab-
lation had the highest efficacy, but the 95% credible inter-
val for ablation was very wide. The widths of the credible
intervals reflect the various sources of uncertainty taken
into account in the Bayesian model. Thus, more evidence
is needed, particularly for the classes of oral treatments.
Besides the sparse and fragmented nature of the evi-
dence network, an important source of uncertainty arose
from having to estimate % MBL < 80 mL or % PBAC <
100 from summary statistics. Consistent reporting of an
outcome measure, reflecting a consensus of investigators
studying HMB, could do much to reduce this uncertainty.
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